Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Santa Rosa, CA
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Hollywood, FL
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Columbus, GA
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Columbus, GA
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Hinsdale, IL
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Lansing, MI
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Lansing, MI
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Southfield, MI
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Southfield, MI
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Hattiesburg, MS
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
St. Louis, MT
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
St. Louis, MT
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Rochester, NY
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Abington, PA
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Abington, PA
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Greenville, SC
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Chattanooga, TN
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Calgary,
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Cleveland Clinic
mi
from
Cleveland, OH
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Duke University
mi
from
Durham, NC
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Ohio State University
mi
from
Columbus, OH
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
University of Chicago
mi
from
Chicago, IL
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Univ of Minnesota
mi
from
Minneapolis, MN
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
West Virginia University
mi
from
Morgantown, WV
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Emory University
mi
from
Atlanta, GA
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
The Mayo Clinic
mi
from
Rochester, MN
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Washington University
mi
from
Saint Louis, MO
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Orange, CA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Miami, FL
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Tampa, FL
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Atlanta, GA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Westwood, KA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Westwood, KA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Louisville, KY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
New York, NY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Rochester, NY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Dallas, TX
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Galveston, TX
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Galveston, TX
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
mi
from
Seattle, WA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
mi
from
Washington, D.C.,
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
509
mi
from
Graz,
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
509
mi
from
Graz,
Click here to add this to my saved trials
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  6/14/2017
Paoli Memorial Hospital
mi
from
Paoli, PA
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 6/14/2017
Paoli Memorial Hospital
mi
from
Paoli, PA
Click here to add this to my saved trials
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  6/14/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 6/14/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/15/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/15/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/15/2017
University of California at San Francisco
mi
from
San Francisco, CA
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/15/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
Status: Enrolling
Updated:  6/15/2017
West County Plastic Surgeons of Washington University
mi
from
Saint Louis, MO
Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
Status: Enrolling
Updated: 6/15/2017
West County Plastic Surgeons of Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  6/15/2017
University of Pittsbutgh Cancer Institute
mi
from
Pittsburgh, PA
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 6/15/2017
University of Pittsbutgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated:  6/15/2017
Markey Cancer Center
mi
from
Lexington, KY
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated: 6/15/2017
Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated:  6/15/2017
Ohio State University
mi
from
Columbus, OH
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated: 6/15/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated:  6/15/2017
Penn State University
mi
from
University Park, PA
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated: 6/15/2017
Penn State University
mi
from
University Park, PA
Click here to add this to my saved trials